What is the projected market valuation of the Pharmaceutical Excipients Market by 2035?

The Pharmaceutical Excipients Market is projected to reach a valuation of 21.16 USD Billion by 2035. Read More

What was the market valuation of the Pharmaceutical Excipients Industry in 2024?

In 2024, the overall market valuation was 10.02 USD Billion. Read More

What is the expected CAGR for the Pharmaceutical Excipients Market during the forecast period 2025 - 2035?

The expected CAGR for the Pharmaceutical Excipients Market during the forecast period 2025 - 2035 is 7.03%. Read More

Which segment of the Pharmaceutical Excipients Industry had the highest valuation in 2024?

The Coatings segment had the highest valuation at 3.52 USD Billion in 2024. Read More

What are the key players in the Global Market?

Key players in the market include BASF SE, Dow Chemical Company, Evonik Industries AG, and Merck KGaA. Read More

How much is the Diluents segment projected to grow by 2035?

The Diluents segment is projected to grow from 2.0 USD Billion in 2024 to 4.2 USD Billion by 2035. Read More

What is the valuation of the Solid Formulations segment in 2024?

The Solid Formulations segment was valued at 3.0 USD Billion in 2024. Read More

Which end-use segment is expected to show significant growth by 2035?

The Pharmaceutical Companies end-use segment is expected to grow from 4.01 USD Billion in 2024 to 8.5 USD Billion by 2035. Read More

What is the projected valuation for Natural Excipients by 2035?

Natural Excipients are projected to reach a valuation of 5.3 USD Billion by 2035. Read More

How does the market for Synthetic Excipients compare to that of Organic Excipients in 2024?

In 2024, the market for Synthetic Excipients was valued at 3.0 USD Billion, while Organic Excipients were valued at 2.5 USD Billion. Read More

Pharmaceutical Excipients Market

ID: MRFR/HC/0366-HCR

200 Pages

Rahul Gotadki

Last Updated: May 06, 2026

Pharmaceutical Excipients Market Research Report: Size, Share, Trend Analysis By Functionality (Binders, Diluents, Disintegrants, Lubricants, Coatings), By Types (Organic Excipients, Inorganic Excipients, Natural Excipients, Synthetic Excipients), By Formulation Type (Solid Formulations, Liquid Formulations, Semi-Solid Formulations, Novel Drug Delivery Systems), By End Use (Pharmaceutical Companies, Contract Manufacturing Organizations, Research Institutions) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry - Forecast Till 2035

Pharmaceutical Excipients Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)7.03%

2024 Market Size$ 10.02 Billion

2025 Market Size$ 10.72 Billion

2035 Market Size$ 21.16 Billion

Key Players

Companies such BASF SE

Dow Chemical Company

Evonik Industries AG

FMC Corporation

Ashland Global Holdings Inc.

JRS Pharma

Trends

Growing Demand for Biopharmaceuticals
Focus on Patient-Centric Formulations
Sustainability in Excipients Development

Opportunities

Rise in Chronic Diseases
Increasing R&D Investments
Growing Demand for Personalized Medicine

Summary Table of Contents Segmentation Methodology Download PDF

Certified Researchers

Customize Report

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Functionality (USD Billion) | |
  1. 4.1.1 Binders | |
  2. 4.1.2 Diluents | |
  3. 4.1.3 Disintegrants | |
  4. 4.1.4 Lubricants | |
  5. 4.1.5 Coatings |
2. 4.2 Healthcare, BY Type (USD Billion) | |
  1. 4.2.1 Organic Excipients | |
  2. 4.2.2 Inorganic Excipients | |
  3. 4.2.3 Natural Excipients | |
  4. 4.2.4 Synthetic Excipients |
3. 4.3 Healthcare, BY Formulation Type (USD Billion) | |
  1. 4.3.1 Solid Formulations | |
  2. 4.3.2 Liquid Formulations | |
  3. 4.3.3 Semi-Solid Formulations | |
  4. 4.3.4 Novel Drug Delivery Systems |
4. 4.4 Healthcare, BY End Use (USD Billion) | |
  1. 4.4.1 Pharmaceutical Companies | |
  2. 4.4.2 Contract Manufacturing Organizations | |
  3. 4.4.3 Research Institutions |
5. 4.5 Healthcare, BY Region (USD Billion) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 BASF SE (DE) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Dow Chemical Company (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Evonik Industries AG (DE) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 FMC Corporation (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Ashland Global Holdings Inc. (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 JRS Pharma (DE) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Merck KGaA (DE) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Siegfried AG (CH) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Colorcon (US) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY FUNCTIONALITY |
7. 6.4 US MARKET ANALYSIS BY TYPE |
8. 6.5 US MARKET ANALYSIS BY FORMULATION TYPE |
9. 6.6 US MARKET ANALYSIS BY END USE |
10. 6.7 CANADA MARKET ANALYSIS BY FUNCTIONALITY |
11. 6.8 CANADA MARKET ANALYSIS BY TYPE |
12. 6.9 CANADA MARKET ANALYSIS BY FORMULATION TYPE |
13. 6.10 CANADA MARKET ANALYSIS BY END USE |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY FUNCTIONALITY |
16. 6.13 GERMANY MARKET ANALYSIS BY TYPE |
17. 6.14 GERMANY MARKET ANALYSIS BY FORMULATION TYPE |
18. 6.15 GERMANY MARKET ANALYSIS BY END USE |
19. 6.16 UK MARKET ANALYSIS BY FUNCTIONALITY |
20. 6.17 UK MARKET ANALYSIS BY TYPE |
21. 6.18 UK MARKET ANALYSIS BY FORMULATION TYPE |
22. 6.19 UK MARKET ANALYSIS BY END USE |
23. 6.20 FRANCE MARKET ANALYSIS BY FUNCTIONALITY |
24. 6.21 FRANCE MARKET ANALYSIS BY TYPE |
25. 6.22 FRANCE MARKET ANALYSIS BY FORMULATION TYPE |
26. 6.23 FRANCE MARKET ANALYSIS BY END USE |
27. 6.24 RUSSIA MARKET ANALYSIS BY FUNCTIONALITY |
28. 6.25 RUSSIA MARKET ANALYSIS BY TYPE |
29. 6.26 RUSSIA MARKET ANALYSIS BY FORMULATION TYPE |
30. 6.27 RUSSIA MARKET ANALYSIS BY END USE |
31. 6.28 ITALY MARKET ANALYSIS BY FUNCTIONALITY |
32. 6.29 ITALY MARKET ANALYSIS BY TYPE |
33. 6.30 ITALY MARKET ANALYSIS BY FORMULATION TYPE |
34. 6.31 ITALY MARKET ANALYSIS BY END USE |
35. 6.32 SPAIN MARKET ANALYSIS BY FUNCTIONALITY |
36. 6.33 SPAIN MARKET ANALYSIS BY TYPE |
37. 6.34 SPAIN MARKET ANALYSIS BY FORMULATION TYPE |
38. 6.35 SPAIN MARKET ANALYSIS BY END USE |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY FUNCTIONALITY |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY TYPE |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY FORMULATION TYPE |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY END USE |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY FUNCTIONALITY |
45. 6.42 CHINA MARKET ANALYSIS BY TYPE |
46. 6.43 CHINA MARKET ANALYSIS BY FORMULATION TYPE |
47. 6.44 CHINA MARKET ANALYSIS BY END USE |
48. 6.45 INDIA MARKET ANALYSIS BY FUNCTIONALITY |
49. 6.46 INDIA MARKET ANALYSIS BY TYPE |
50. 6.47 INDIA MARKET ANALYSIS BY FORMULATION TYPE |
51. 6.48 INDIA MARKET ANALYSIS BY END USE |
52. 6.49 JAPAN MARKET ANALYSIS BY FUNCTIONALITY |
53. 6.50 JAPAN MARKET ANALYSIS BY TYPE |
54. 6.51 JAPAN MARKET ANALYSIS BY FORMULATION TYPE |
55. 6.52 JAPAN MARKET ANALYSIS BY END USE |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY FUNCTIONALITY |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY TYPE |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY FORMULATION TYPE |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY END USE |
60. 6.57 MALAYSIA MARKET ANALYSIS BY FUNCTIONALITY |
61. 6.58 MALAYSIA MARKET ANALYSIS BY TYPE |
62. 6.59 MALAYSIA MARKET ANALYSIS BY FORMULATION TYPE |
63. 6.60 MALAYSIA MARKET ANALYSIS BY END USE |
64. 6.61 THAILAND MARKET ANALYSIS BY FUNCTIONALITY |
65. 6.62 THAILAND MARKET ANALYSIS BY TYPE |
66. 6.63 THAILAND MARKET ANALYSIS BY FORMULATION TYPE |
67. 6.64 THAILAND MARKET ANALYSIS BY END USE |
68. 6.65 INDONESIA MARKET ANALYSIS BY FUNCTIONALITY |
69. 6.66 INDONESIA MARKET ANALYSIS BY TYPE |
70. 6.67 INDONESIA MARKET ANALYSIS BY FORMULATION TYPE |
71. 6.68 INDONESIA MARKET ANALYSIS BY END USE |
72. 6.69 REST OF APAC MARKET ANALYSIS BY FUNCTIONALITY |
73. 6.70 REST OF APAC MARKET ANALYSIS BY TYPE |
74. 6.71 REST OF APAC MARKET ANALYSIS BY FORMULATION TYPE |
75. 6.72 REST OF APAC MARKET ANALYSIS BY END USE |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY FUNCTIONALITY |
78. 6.75 BRAZIL MARKET ANALYSIS BY TYPE |
79. 6.76 BRAZIL MARKET ANALYSIS BY FORMULATION TYPE |
80. 6.77 BRAZIL MARKET ANALYSIS BY END USE |
81. 6.78 MEXICO MARKET ANALYSIS BY FUNCTIONALITY |
82. 6.79 MEXICO MARKET ANALYSIS BY TYPE |
83. 6.80 MEXICO MARKET ANALYSIS BY FORMULATION TYPE |
84. 6.81 MEXICO MARKET ANALYSIS BY END USE |
85. 6.82 ARGENTINA MARKET ANALYSIS BY FUNCTIONALITY |
86. 6.83 ARGENTINA MARKET ANALYSIS BY TYPE |
87. 6.84 ARGENTINA MARKET ANALYSIS BY FORMULATION TYPE |
88. 6.85 ARGENTINA MARKET ANALYSIS BY END USE |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY FUNCTIONALITY |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY FORMULATION TYPE |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USE |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY FUNCTIONALITY |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY TYPE |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY FORMULATION TYPE |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY END USE |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY FUNCTIONALITY |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY TYPE |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY FORMULATION TYPE |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY END USE |
102. 6.99 REST OF MEA MARKET ANALYSIS BY FUNCTIONALITY |
103. 6.100 REST OF MEA MARKET ANALYSIS BY TYPE |
104. 6.101 REST OF MEA MARKET ANALYSIS BY FORMULATION TYPE |
105. 6.102 REST OF MEA MARKET ANALYSIS BY END USE |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY FUNCTIONALITY, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY FUNCTIONALITY, 2024 TO 2035 (USD Billion) |
114. 6.111 HEALTHCARE, BY TYPE, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion) |
116. 6.113 HEALTHCARE, BY FORMULATION TYPE, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY FORMULATION TYPE, 2024 TO 2035 (USD Billion) |
118. 6.115 HEALTHCARE, BY END USE, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY TYPE, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY END USE, 2025-2035 (USD Billion) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY TYPE, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY END USE, 2025-2035 (USD Billion) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY TYPE, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY END USE, 2025-2035 (USD Billion) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY TYPE, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY END USE, 2025-2035 (USD Billion) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY TYPE, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY END USE, 2025-2035 (USD Billion) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY TYPE, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY END USE, 2025-2035 (USD Billion) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY TYPE, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY END USE, 2025-2035 (USD Billion) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY TYPE, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY END USE, 2025-2035 (USD Billion) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY TYPE, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY END USE, 2025-2035 (USD Billion) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY TYPE, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY END USE, 2025-2035 (USD Billion) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY TYPE, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY END USE, 2025-2035 (USD Billion) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY TYPE, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY END USE, 2025-2035 (USD Billion) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY TYPE, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY END USE, 2025-2035 (USD Billion) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY TYPE, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY END USE, 2025-2035 (USD Billion) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY TYPE, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY END USE, 2025-2035 (USD Billion) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY TYPE, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY END USE, 2025-2035 (USD Billion) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY TYPE, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY END USE, 2025-2035 (USD Billion) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY TYPE, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY END USE, 2025-2035 (USD Billion) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY TYPE, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY END USE, 2025-2035 (USD Billion) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY TYPE, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY END USE, 2025-2035 (USD Billion) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY TYPE, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY END USE, 2025-2035 (USD Billion) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY TYPE, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY END USE, 2025-2035 (USD Billion) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY TYPE, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY END USE, 2025-2035 (USD Billion) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY TYPE, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY END USE, 2025-2035 (USD Billion) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY TYPE, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY END USE, 2025-2035 (USD Billion) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY TYPE, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY END USE, 2025-2035 (USD Billion) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY TYPE, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY END USE, 2025-2035 (USD Billion) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY TYPE, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY END USE, 2025-2035 (USD Billion) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY TYPE, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY END USE, 2025-2035 (USD Billion) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Pharmaceutical Excipients Market Segmentation

Pharmaceutical Excipients Market By Functionality (USD Billion, 2025-2035)

Binders
Diluents
Disintegrants
Lubricants
Coatings

Pharmaceutical Excipients Market By Type (USD Billion, 2025-2035)

Organic Excipients
Inorganic Excipients
Natural Excipients
Synthetic Excipients

Pharmaceutical Excipients Market By Formulation Type (USD Billion, 2025-2035)

Solid Formulations
Liquid Formulations
Semi-Solid Formulations
Novel Drug Delivery Systems

Pharmaceutical Excipients Market By End Use (USD Billion, 2025-2035)

Pharmaceutical Companies
Contract Manufacturing Organizations
Research Institutions

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”